Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
About this item
Full title
Author / Creator
Bardia, Aditya , Hu, Xichun , Dent, Rebecca , Yonemori, Kan , Barrios, Carlos H. , O’Shaughnessy, Joyce A. , Wildiers, Hans , Pierga, Jean-Yves , Zhang, Qingyuan , Saura, Cristina , Biganzoli, Laura , Sohn, Joohyuk , Im, Seock-Ah , Lévy, Christelle , Jacot, William , Begbie, Natasha , Ke, Jun , Patel, Gargi , Curigliano, Giuseppe and DESTINY-Breast06 Trial Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy.
Alternative Titles
Full title
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Authors, Artists and Contributors
Author / Creator
Hu, Xichun
Dent, Rebecca
Yonemori, Kan
Barrios, Carlos H.
O’Shaughnessy, Joyce A.
Wildiers, Hans
Pierga, Jean-Yves
Zhang, Qingyuan
Saura, Cristina
Biganzoli, Laura
Sohn, Joohyuk
Im, Seock-Ah
Lévy, Christelle
Jacot, William
Begbie, Natasha
Ke, Jun
Patel, Gargi
Curigliano, Giuseppe
DESTINY-Breast06 Trial Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3106043750
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3106043750
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2407086
